As a pharmaceutical manufacturer, SANOCHEMIA utilises its entire value chain (R&D, API production and the manufacture of finished pharmaceuticals) in order to implement appropriate market development strategies. The aim here is to identify approaches which will lead to an increase in the value of the company. This includes expansion into growing pharmaceutical markets, so-called pharmerging markets, as well as the development of core markets such as Germany and the future development of the US and Chinese markets. In addition, the company is continuously working on expanding its product portfolio in order to achieve greater market penetration.

The current Covid-19 pandemic opens up particular strategic potential for SANOCHEMIA in its home market: the company is one of the few companies in Austria to have maintained production, technology and know-how in Europe at all times. As a manufacturer with an all-purpose production facility for APIs, SANOCHEMIA can make a significant contribution to domestic security of supply of critical pharmaceuticals.

Since April 2020, SANOCHEMIA has been operating as a limited liability company and is now owned by a consortium consisting of EOSS Industries Holding (49.9%), b.e imaging (35.81%) and Wirtschaft Burgenland (14.29%).

EOSS Industries is an Austrian powerhouse in the field of innovative future technologies. With its four divisions Life Sciences/Med-Tech, Smart Enterprise & Country, Future Commerce and Digital Platforms, the company serves major clients from numerous industries. EOSS combines the advantages of an integrated technology company with the innovative power and flexibility of a strategic holding company. The medium-sized company has its headquarters in Graz and locations in Austria, Germany and Southeast Europe.

b.e. imaging is part of the bender group, which is a medium-sized family business with around 150 employees in Germany, Austria and Switzerland. The bender group has been active in the fields of radiology and urology for many decades. The shareholders of the parent companies b.e.imaging and röntgen bender are the families Bender and Eckhardt. The two parent companies have shareholdings in several subsidiaries. Together they all form the bender group.

Wirtschaft Burgenland (WiBuG) is the economic agency of the federal state of Burgenland. Its aim is to promote the location Burgenland in a sustainable way. On the one hand, the WiBuG implements economic policy measures through subsidies, participations and active company settlements. On the other hand, it offers companies a comprehensive package of support programmes, its own financing companies and numerous services.

Commitment to responsibility

"Compliance is the totality of all measures in a company to ensure the lawful conduct of persons associated with the company".

Cooperation between pharmaceutical companies and members of professional circles and institutions is important and necessary. It serves the well-being of the patient and the continuous improvement of his medical care. The disclosure of benefits of monetary value strengthens trust in this cooperation.

As a member of Pharmig, SANOCHEMIA is committed to the Pharmig Code of Conduct. Article 9 (Transparency) of the Code of Conduct provides for the disclosure of non-monetary benefits resulting from cooperation between pharmaceutical companies and healthcare professionals (doctors, pharmacists, etc.) and institutions (hospitals, professional societies, etc.).

Disclosure under Article 9 CoC-Pharmig

2020
2018
2017
2016

Details on disclosure and the PHARMIG Code of Conduct can be found at: www.pharmig.at

Commitment to responsibility

In addition to complying with all national and international laws and guidelines, SANOCHEMIA employees are obliged to act in accordance with SANOCHEMIA principles. SANOCHEMIA conducts regular training sessions on the subject of compliance to ensure that all employees are familiar with the principles and adhere to them.

The SANOCHEMIA Compliance Management System:

Avoidance: Guidelines, training, consulting

Recognize: Risk assessment, standardized reporting process, unannounced audits

Response: Case investigation / internal investigations, sanctions, cooperation with authorities

The Compliance Management System of SANOCHEMIA Pharmazeutika GmbH:

SANOCHEMIA operates worldwide via a large number of distribution partners. SANOCHEMIA communicates its principles to these partner companies and expects them to comply with all regulatory requirements and to treat resources, the environment and employees responsibly.

social - ethical - economic - environmentally compatible

SANOCHEMIA is an internationally active pharmaceutical company. As such, SANOCHEMIA is committed not only to manufacturing products of the highest quality, but also to fulfilling its responsibilities towards society and the environment through fair, ethical, sustainable and transparent conduct.

Principles, not loopholes" is the motto which is reflected in the Group-wide compliance programme. In five units, principles are defined which SANOCHEMIA's managers and employees apply in order to act in a socially, ethically and economically responsible manner, to conserve resources and protect the environment.

We collect and document the occurrence of side effects with our products.
 If you wish to report a side effect, please contact us:

e-mail: drug.safety@sanochemia.com

In the event of a side effect report, please provide us with at least the following data:

• The product concerned
• information on the patient (age, sex)
• Possible detailed description of the side effect
• Your contact details (for possible queries)